期刊文献+

冠脉内置入药物涂层支架与金属裸支架对冠心病患者血浆C反应蛋白水平的影响 被引量:1

Effects of drug-eluting stent and bare metal stent on plasma C-reactive protein level in patient with coronary heart disease
下载PDF
导出
摘要 目的:探讨冠脉内置入药物涂层支架(DES)和金属裸支架(BMS)对冠心病患者血浆C反应蛋白(CRP)水平的影响。方法:置入单个支架的稳定型心绞痛患者83例,其中成功置入DES 43例,成功置入BMS 40例,另选同期住院行冠脉造影检查显示冠状动脉不同程度狭窄而未行PCI的冠心病患者35例作对照,3组年龄、性别、身体状况、病变血管差异无统计学意义(P>0.05)。分别于术前和术后48、72 h和2周取静脉血2 mL,测定血浆CRP水平。结果:术前3组血浆CRP水平差异无统计学意义(P>0.05),术后48、72 h DES和BMS组血浆CRP水平均较对照组升高,但DES组升高幅度较小(P<0.05)。术后2周3组血浆CRP水平差异无统计学意义(P>0.05)。结论:DES可能不会引发PCI术后的急性炎症反应。 Aim:To explore the effects of drug-eluting stents(DES) and bare metal stent(BMS) implantation on plasma C-reactive protein(CRP) levels of coronary heart disease(CHD) patients.Methods:A total of 83 patients with CHD were performed by percutaneous coronary intervention(PCI) with a single stent implantation,and 43 patients were implanted DES and 40 with BMS.35 patients with coronary artery stenosis exceeding 70% but without PCI were the control group.Plasma CRP levels were measured before intervention and at 48,72 hours,2 weeks after coronary stenting.Results: There was no difference in clinical and angiographic baseline characteristics among the three groups(P〉0.05).48,72 h after PCI,the plasma CRP levels in DES and BMS groups were significantly higher than those of the control group(P〈0.01),moreover the CRP levels were significantly lower in the DES group than that in the BMS group(P〈0.01).Two weeks after PCI,the plasma CRP levels in DES and BMS groups didn't differ from those of the control group(P〈0.01),respectively.Conclusion: It indicated that DES couldn′t induce acute imflammation after PCI.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2008年第6期1204-1206,共3页 Journal of Zhengzhou University(Medical Sciences)
关键词 药物涂层支架 金属裸支架 C反应蛋白 冠心病 drug-eluting stent bare metal stent C-reactive protein coronary heart disease
  • 相关文献

参考文献10

  • 1Wilson SH, Berger PB, Mathew V, et al. Immediate and late outcomes after direct stent implantation without balloon predilatation[J]. J Am Coll Cardiol,2000,35(4):937
  • 2Urban P, Gershlick AH,Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice:one- year follow-up of the e-Cypher registry [ J ]. Circulation, 2006,113(11):1 434
  • 3沈青山,刘永胜,朱锐,付度关,汤永谦,陶红,李素珍,叶剑文.氟伐他汀干预治疗对不稳定性心绞痛患者介入治疗后炎症因子影响的研究[J].中华心血管病杂志,2005,33(4):320-322. 被引量:26
  • 4Farb A, Sangiorgi G, Carter AJ,et al. Pathology of acute and chronic coronary stenting in humans [ J ]. Circulation,1999,99(1) :44
  • 5Saito M, Ishimitsu T, Minami J, et al. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovas- cular risk factors [ J ]. Atherosclerosis, 2003,167 ( 1 ) :73
  • 6李嘉强.炎症标志物与冠心病[J].心血管病学进展,2003,24(3):235-236. 被引量:32
  • 7Mulvihill NT, Foley JB. Inflammation in acute coronary syndrome[ J]. Heart ,2002,87 ( 3 ) :201
  • 8Angioi M, Abdelmouttaleb I, Rodriguez RM, et al. Increased C-reactive protein levels in patients with in-stent restenosis and its implications[ J]. Am J Cardiol,2001,87(10) :1 189
  • 9Gaspardone A,Crea F,Versaci F,et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina [ J ]. Am J Cardiol, 1998,82 (4) :515
  • 10de la Torre-Hernandez JM, Sainz-Laso F, Burgos V, et al. Comparison of C-reactive protein levels after coronary stenting with bare metal versus sirolimus-eluting stents[J]. Am J Cardiol,2005,95 (6) :748

二级参考文献8

  • 1Prevention of cardiovascular events and death with Pravastatin in patients with coronary heart disease and a broad rang of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med, 1998,339: 1349-1357.
  • 2Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.JAMA, 2002 ,287:3215-3222.
  • 3Ruygrok PN, de Jaegere PT, van Domburg RT, et al. Clinical outcome 10 years after attempted percutaneous transluminal coronary angioplasty in 856 patients. J Am Coll Cardiol, 1996,27: 1669-1677.
  • 4Wilson SH, Berger PB, Mathew V, et al. Immediate and late outcomes after direct stent implantation without ballon predilation. J Am Coll Cardiol, 2000, 35: 937-943.
  • 5Ravkilde J, Nissen H, Mickley H, et al. Cardiac troponin T and CK-MB mass release after visually successful percutaneous transluminal coronary angioplasty in stable angina pectoris. Am Heart J, 1994,127: 13-20.
  • 6Harrington RA. Cardiac enzyme elevation after percutaneous coronary intervention:myonecrosis, the coronary microcirculation and mortality. J Am Coll Cardiol, 2000,35: 1142-1144.
  • 7Serruys PW, Foley DP, Jackson G, et al.A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary ballon angioplasty: final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J, 1999,20: 58-69.
  • 8Mulder HJ, Bal ET, Jukema JW, et al. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am J Cardiol, 2000,86: 742-746.

共引文献54

同被引文献10

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部